China Announces Retaliatory Sanctions On Marco Rubio, Ted Cruz And Other Top US Senators

China Announces Retaliatory Sanctions On Marco Rubio, Ted Cruz And Other Top US Senators

Tyler Durden

Mon, 07/13/2020 – 08:11

China announced sanctions against several key US politicians in retaliation for measures announced by the Trump administration last week to punish senior Chinese officials over Beijing’s human rights abuses against minority Uighur Muslims, reported Reuters.

Chinese Foreign Ministry spokeswoman Hua Chunying told reporters at a press conference Monday that effective immediately, Beijing will sanction four top US officials.

Hua said, “corresponding sanctions” were applied to Republican Senators Marco Rubio and Ted Cruz, US Representative Chris Smith, Ambassador at Large for International Religious Freedom Sam Brownback, and the Congressional-Executive Commission on China.

“The US actions seriously interfere in China’s internal affairs, seriously violate the basic norms of international relations and seriously damage Sino-U.S. relations,” she said during the briefing adding that “China will make further responses based on how the situation develops,” though limited details were given on what the sanctions would entail. 

The tit-for-tat diplomatic spat between the US and China comes days after Washington imposed travel bans on Chinese Communist Party (CCP) officials for their involvement in restricting foreigners’ access to Tibet. Shortly after, China responded by issuing visa restrictions on Americans for the region. 

Last week, Chinese Foreign Ministry spokesman Zhao Lijian told reporters in Beijing: The US “should stop going further down the wrong path to avoid further harming China-U.S. relations and communication and cooperation between the two countries.” 

Sino-US relations have plunged to their lowest point in decades since the trade war began, amid the coronavirus pandemic, Hong Kong debacle, Taiwan tensions and fresh hostilities in the South China Sea.

President Trump announced late last week a phase two trade deal with China is “unlikely,” suggesting relations between both countries will plunge further. 

via ZeroHedge News https://ift.tt/3ejEKzq Tyler Durden

Futures Jump Above 3,200 On Vaccine Optimism, Merger Monday

Futures Jump Above 3,200 On Vaccine Optimism, Merger Monday

Tyler Durden

Mon, 07/13/2020 – 08:01

With futures flat for much of the overnight session, markets needed that extra oomph to start the week and push them above a key psychological level, and they got that after news that Pfizer and German biotech BioNTech SE were granted fast track designation by the FDA for two of the companies’ four vaccine candidates against the coronavirus. The news, which is purely procedural and was expected all along, was misinterpreted by the market as if the two companies have a promising virus vaccine, and sent Pfizer shares 2%, while BioNTech jumped 5%. More importantly, the news was enough to push Eminis up more than 21 point and above 3,200 which will surely help the market’s mood ahead of tomorrow’s official start of Q2 earnings which are expected to be the worst since the financial crisis.

In corporate news, Pepsi kicked off the second-quarter earnings season on a bright note, gaining over 2% as it benefited from a surge in at-home consumption of salty snacks such as Fritos and Cheetos during lockdowns, while a multi-billion dollar semiconductor deal also lifting the mood. Analog Devices rose 0.9% in premarket trading after it confirmed a Sunday report from the WSJ, offering to buy peer Maxim Integrated Products Inc for $20.91 billion in an all-stock deal. Maxim shares jumped 17%.

The renewed covid optimism and strong results offered some cheer as investors are bracing for what could be the sharpest drop in quarterly earnings for S&P 500 firms since the financial crisis, with Goldman expected a 60% drop in Q2 EPS.

Results from big banks will be in focus this week. The April-June reports will reveal the extent of the damage wreaked by the coronavirus-induced lockdowns on corporate profits. With a record jump in cases in the United States and some other hotspots around the world, analysts have predicted a return to S&P 500 earning s growth only by 2022. Recent economic data, however, has pointed to a revival in business activity, helping the Nasdaq clinch its sixth record close in seven weeks on Friday as broader markets rose on positive data from Gilead’s potential COVID-19 treatment.

Earlier in the session, Asian stocks gained, led by materials and industrials, after falling in the last session. Markets in the region were mixed, with Japan’s Topix Index rising, and Singapore’s Straits Times Index and Thailand’s SET falling. Amusingly, Beijing appears to be losing control of its stock market bubble, as the Shanghai Composite brushes off another mainland media call for ‘rational’ behavior to gain 1.8%, Shenzhen 2.7% higher.

Trading volume for MSCI Asia Pacific Index members was 42% above the monthly average. The Topix gained 2.5%, with AIT and Nomura System Corp rising the most. The Shanghai Composite Index rose 1.8%, with Xinhu Zhongbao and Flying Technology posting the biggest advances

European markets initially failed to echo Asia’s optimism, with the majority of indexes trading well off opening levels. FTSE MIB underperformed, trading flat after opening ~1.5% higher. Banks, autos and travel names gave back ~1% of gains, having outperformed in early trading. However, as US traders walked in, European share rose alongside US bond yields.

And so, with global stocks trading near their highest since February, focus now turns to whether the profit outlook will back up bullishness fueled by central bank and fiscal policy support. Traders have largely shrugged off new coronavirus outbreaks in some parts of the world, with Florida on Sunday posting the biggest one-day rise in cases since the pandemic began in the U.S., reporting 15,300 new infections. As Bloomberg notes, “there’s reason for optimism even though earnings are estimated to have contracted by more than 40% in the worst quarter since the financial crisis, as analysts upgrade their forecasts for the rest of the year.”

“We think earnings are likely to recover in the second half of the year and excess liquidity will continue to support risk assets,” said Julie Fox at UBS Private Wealth Management. “We see further potential in global equities and think there’s some upside in segments of the market that have underperformed during the crisis.”

In rates, Treasuries were unchanged after trading in a narrow range, the 10Y moving from 0.625% to 0.655% during the European session and within 2bps of Friday’s closing levels, having pared declines as U.S. equity index futures tracked European stocks higher, TSYs outperformed other developed market bonds which were pressured by supply; there’s no Treasury coupon supply this week. Yields so far remain inside Friday’s ranges, which featured multi-month lows for all tenors and a record low for the 5-year. The 10-year yield was little changed at 0.646%, traded at 0.5678% Friday, lowest yield since April 22. German and U.K. 10-year yields were 2bp-3bp cheaper vs U.S., while Japan’s and Australia’s bond markets were pressured by supply. Peripheral spreads traded off session wides as BTPs and PGBs put in a firm bounce off the lows.

In FX, the dollar traded mixed versus its Group-of-10 peers and hovered around 1.13 per euro; most currencies were confined to narrow moves as they consolidated recent trading ranges. The Bloomberg dollar index faded Asia’s losses to trade flat. Cable traded near 1.2600, having printed highs of 1.2666. The Australian dollar was on the top of the table while the New Zealand dollar slipped; asset managers last week increased Aussie long positions to the most since September 2017 and decreased kiwi longs for the first time in a month, Commitments of Traders (COT) reports showed. Norway’s krone fell versus all Group-of-10 peers as oil edged lower ahead of an OPEC+ meeting this week at which the group may announce plans to start tapering historic production cuts even as the coronavirus surges unabated in many parts of the world.

In commodities, crude futures drifted lower, front-month WTI dips below $40 ahead of an OPEC+ meeting at which the group may announce plans to start tapering historic production cuts.
 

Market Snapshot

  • S&P 500 futures up 0.2% to 3,183.50
  • STOXX Europe 600 up 0.3% to 367.88
  • MXAP up 1.1% to 166.56
  • MXAPJ up 0.7% to 551.10
  • Nikkei up 2.2% to 22,784.74
  • Topix up 2.5% to 1,573.02
  • Hang Seng Index up 0.2% to 25,772.12
  • Shanghai Composite up 1.8% to 3,443.29
  • Sensex down 0.04% to 36,578.49
  • Australia S&P/ASX 200 up 1% to 5,977.52
  • Kospi up 1.7% to 2,186.06
  • German 10Y yield rose 0.4 bps to -0.461%
  • Euro up 0.06% to $1.1307
  • Italian 10Y yield rose 0.2 bps to 1.099%
  • Spanish 10Y yield rose 1.1 bps to 0.424%
  • Brent futures down 1.4% to $42.65/bbl
  • Gold spot up 0.5% to $1,808.06
  • U.S. Dollar Index little changed at 96.61

Top Overnight News from Bloomberg

  • When the ECB meets this week to review its radical suite of measures to revive the economy, there’s one tool it insists it’ll stay away from: yield curve control
  • Faced with the prospect of restricted access to U.S. dollars, China’s answer is to get more people to use its own currency instead
  • The dollar rallied during the March market turmoil due to its haven status, yet ongoing repricing in options may be challenging the idea that a second wave of the pandemic or another black swan event could see similar results
  • China announced sanctions against U.S. officials including Senators Marco Rubio and Ted Cruz, in a largely symbolic retaliation over legislation intended to punish Beijing for its treatment of ethnic minorities in the Xinjiang region
  • Boris Johnson’s government will launch a campaign Monday to urge businesses to prepare for the end of the Brexit transition period on Dec. 31, as a survey showed only a quarter of directors said their companies were fully ready
  • France will unveil “massive” support for youth employment this week and a new broad stimulus plan including tax cuts for companies at the end of August, Finance Minister Bruno Le Maire said

Asian equity markets began the week mostly positive as the region benefitted from the recent tailwinds from Wall St. where encouraging Remdesivir data and outperformance in financials last Friday ahead of upcoming earnings, helped markets shrug off the rising COVID infection numbers to lift all major US indices and helped the Nasdaq to a fresh all-time high. ASX 200 (+1.0%) was led higher by outperformance in utilities and the top-weighted financials sector, as the latter took its cue from its counterpart stateside and as big 4 bank Westpac was buoyed by reports it is mulling divesting over AUD 4bln in non-core wealth assets, while Nikkei 225 (+2.2%) outperformed on a break above the 22,500 level with participants unfazed by the increasing risks associated with the outbreak flare-up in Tokyo. Hang Seng (+0.2%) and Shanghai Comp. (+1.8%) were also positive after the PBoC provided its first liquidity injection following a 2-week hiatus and amid recent better than expected lending data from China. This helped domestic markets shake off the initial tentativeness after local press continued to urge rationality regarding stocks and amid the continued US-China tensions with US President Trump suggesting a Phase 2 trade deal was unlikely at this point and the US State Department warned US citizens in China of increased arbitrary detention, while China had also threatened to impose reciprocal measures if the US insists on moving forward with sanctions. Finally, 10yr JGBs were weaker amid gains in stocks and spillover selling following Friday’s pullback in USTs, while the lack of BoJ presence in the market ahead of its 2-day policy meeting tomorrow, also contributed to the tame demand for bonds.

Top Asian News

  • Tokyo Virus Numbers Fuel Concern of Spread Beyond Nightclubs
  • After 133% Rally, SoftBank Investors Bet There’s More Ahead
  • Netanyahu Ally Calls for Immediate Lockdown to Halt Virus Spread

European equities have kicked the week off on the front-foot (Eurostoxx 50 +0.8%) in an extension of the gains seen last week as markets thus far continue to shrug off the rising global COVID-19 case count whereby the WHO reported a record daily increase of over 230k cases in a 24 hour period over the weekend. From a European perspective, it is worth noting that the WHO stated that the largest increases in cases were seen in the US, Brazil, India and South Africa and therefore a bulk of the focus currently resides outside the continent. Furthermore, some desks have attributed the positive sentiment thus far to mounting hopes ahead of the upcoming EU summit as the bloc continues to negotiate its recovery fund. That said, work is still be done on appeasing the so-called “frugal four” and as such, some have cautioned that a deal might not come until later in the month. Gains in Europe are currently favouring cyclical names with autos, basic resources and travel & leisure names outperforming peers. However, as European indices pullback from earlier session highs, the composition of sector-wide performance could stage a rotation if sentiment deteriorates further. In terms of stock specifics, Akzo Nobel (+4.1%) trade higher after posting a Q2 update, whilst the same can also be said for the likes of DNB (+10.8%) and G4S (+8.7%). To the downside, the main outlier is Atlantia (-15.5%) after Italian PM Conte warned that proposals from the Co. are unsatisfactory thus far and the government will not sacrifice public interest over the Co. Additionally, Ubisoft (-9.0%) also trade lower on the session after undertaking multiple personal changes in response to allegations/accusations of misconduct.

Top European News

  • EU Carbon Permits Climb to 14-Year High as Bloc Goes Green
  • G4S Jumps Most Since May; Panmure Notes Security Unit Resilience
  • Ubisoft Drops After Harassment Reports, Analysts Cut Stock
  • Sweden’s Alfa Laval Agrees to Buy Neles in $2 Billion Deal

In FX, although the US Dollar has pared some losses and the DXY is holding above 96.500 within 96.387-685 parameters, the Aussie is still outpacing G10 counterparts in wake of a 2nd consecutive Usd/CNY midpoint fixing below the psychological 7.0000 level and a broad upturn in risk sentiment. Aud/Usd is hovering within a 0.6984-41 range ahead of NAB business conditions and confidence overnight, while the Aud/Nzd cross has rebounded through 1.0600 as the Kiwi lags vs its US peer around 0.6560 in advance of NZ CPI data on Wednesday. Note also, a dovish note from ANZ may be weighing on the Nzd as the bank believes that the RBNZ should carefully consider policies to weaken the exchange rate and is keeping all options on the agenda (ie NIRP).

  • CAD/EUR – The Loonie is also benefiting from the positive risk tone with Usd/Cad meandering from 1.3602 to 1.3556 even though crude prices are softer, while the Euro is just keeping afloat of 1.1300 after topping out ahead of 1.1340 and decent option expiry interest extending to 1.1350 (1 bn).
  • GBP/CHF/JPY – Sterling ran in to supply at 1.2660+ levels again and faded a fraction shy of Friday’s circa 1.2667 high to form a 2nd consecutive marginally lower peak having hit 1.2670 on July 9, and Cable is now striving to retain the 1.2600 handle as Eur/Gbp bounces from just under 0.8950 towards 0.8975 in the run up to the next round of Brexit talks. Also ahead and a potential Pound mover, 2 separate speeches by BoE Governor Bailey. Elsewhere, the Franc is pivoting 0.9400 against the Greenback and 1.0640 vs the Euro following another sizeable increase in Swiss domestic bank sight deposits on the eve of a speech by SNB chair Jordan. Similarly, the Yen is straddling 107.00 and 121.00 vs the single currency after a loss of safe haven premium, and now eyeing Japanese ip tomorrow for some independent impetus.
  • SCANDI/EM – Some loss of bullish momentum for the Norwegian Krona as risk appetite wanes and oil drifts, while the Swedish Crown is also apprehensive awaiting CPI on Tuesday. However, the Turkish Lira has pared some declines in wake of better than expected, albeit still bleak ip and a narrower than forecast current account deficit.

In commodities, WTI and Brent have had a downbeat start to the week with both benchmarks posting losses in excess of 1% and WTI Aug’20 future having dropped back below the USD 40/bbl handle. The most recent declines have arisen as sentiment more broadly takes a slight leg lower; albeit, with European and US equity futures still very much in positive territory. Over the weekend there were a number of updates on the crude front firstly, and one of the likely drivers of the morning’s downside, Saudi Arabia and other producers are seen as likely to increase output in August. In light of the easing of COVID-19 lockdown restrictions but the ongoing spread of cases is weighing on these plans. Additionally, desks note that OPEC+ are to begin easing production cuts from August, a measure which would be in-fitting with the current deal. Further clarity on the plans for OPEC+ ahead will arise from Wednesday’s JMMC meeting; although, it is worth bearing in mind the JMMC do not have the power to set policy themselves, they can only make recommendations to the broader OPEC+ members. Elsewhere, a resumption of woes for Libya’s NOC as the force majeure on all oil exports has been reimplemented, after cargoes docked and loaded late last week at Es Sider, due to LNA saying the blockade is to continue. Turning to metals, spot gold is firmer by some USD 10/oz thus far for the session and resides towards the top end of a relatively confined range which has notable seen the lower end drop beneath USD 1800/oz. Price action for the metal has largely been dictated by the mild pullback in general sentiment and broader USD moves.

US Event Calendar

  • 11:30am: Fed’s Williams Discusses Libor
  • 1pm: Fed’s Kaplan Speaks in Webinar Hosted by National Press Club
  • 2pm: Monthly Budget Statement, est. $863.0b deficit, prior $398.8b deficit

DB’s Jim Reid concludes the overnight wrap

I hope you all had a good weekend. At the start of lockdown we decided to buy a swing, slide and climbing frame set for the garden. We thought the kids could make use of it after we’d had a go ourselves. Three and a half months later, and one week after playgrounds reopened here in the U.K., it arrived at the weekend. I’ve never seen the kids so excited. It made me feel less guilty about playing golf where I am pleased to announce that my comeback from the most dreadful run known to man (or woman) continued. In a field of 144 I was just inside the top 10 shooting my handicap and banishing the previous weekend’s third last (ahead of only two octogenarians) to the dustbin. Readers on Friday will now know I shout “back” and “hit” during my swing to maintain rhythm. Apart from confusing my playing partners it seems to be working for now.

In a week ahead as packed as my golf club is at the moment, the main highlight is the EU summit on Friday where leaders will gather to discuss the recovery fund. In addition to this, we’ll also see the ECB, the Bank of Japan and others make their latest monetary policy decisions. Meanwhile, earnings season kicks off, including a number of US financials reporting. Economic data includes China’s Q2 GDP reading along with a number of June releases out from the US.

More on this below but first the weekend news and Asian market developments. Risk has started the week on the front foot with the Nikkei (+1.89%), Hang Seng (+0.92%), Shanghai Comp (+1.27%) and Kospi (+1.52%) all up. Futures on the S&P 500 are up +0.46% and yields on 10y USTs are down -1.4bps. Spot gold and silver prices are up +0.25% and +0.86% respectively.

Coronavirus cases continued to accelerate over the weekend with the US registering average case growth of +1.95% on Saturday and Sunday combined. This is higher than the last 5 weekends average of +1.38%. In terms of states, Texas registered new case growth of +3.66% vs. the last 5 weekend average of 2.71% and in Florida this stood at +5.13% (vs. 4.45%) and California (+2.11%) in line with previous 5 weekends average. The growth rate of new deaths actually declined slightly for the US overall (+0.35% this weekend vs. +0.39% in the previous 5 weekends) but at state level, Texas (+2.16% vs. 0.80%), Florida (+1.69% vs. +0.80%) and Arizona (+3.66% vs. 1.39%) all saw higher death rates even if the pace of fatalities vs cases is still significantly behind that of the first wave.

Meanwhile, New York City, once the epicenter of the US coronavirus outbreak, reported its first day with zero confirmed or probable virus deaths on Sunday since the pandemic began. Elsewhere, Japan’s economy minister, Yasutoshi Nishimura, said that the country needs to remain on high alert for further coronavirus outbreaks as the number of cases with unclear contagion routes increases and added that testing should be strategically and greatly increased. Japan reported 681 new cases on Sunday with Tokyo reporting more than 200 cases for four straight days.

In terms of other weekend news, here in the UK, the Telegraph reported that Chancellor Sunak is planning sweeping Brexit tax cuts to protect the economy. The report added that the Chancellor is also considering an overhaul of planning laws in up to 10 new ‘freeports’ within a year of the UK becoming fully independent from the EU in December. Meanwhile, the FT has reported overnight that the UK is proposing to withhold power to control state aid from its devolved nations when the Brexit transition ends. This could lead to friction with Scotland and Wales. The report added that the proposal, which would give Westminster statutory powers to control policies for the entire UK, is expected to appear in a bill this autumn laying the legal foundations of a new internal market.

In other news, the New York Times reported that OPEC, Russia and other producers are expected to modestly ease the record production cuts in August as coronavirus lockdowns end and demand begins to rise again. A committee of key officials from OPEC and Russia will meet on Wednesday by video conference to discuss their approach to the market. Oil prices are trading c. -1% this morning.

More on this week now. The EU leaders summit in Brussels on Friday and into Saturday will discuss the recovery fund in response to the pandemic, as well as the EU’s new long-term budget. The baseline expectations from our economists (link here ) is that there will be a deal on the recovery fund at this meeting, but it remains a close call. If an agreement weren’t to be reached there, then they still expect one within weeks. It’s worth remembering that there are number of complex issues to be worked out, including the ratio of grants to loans, with the so-called “frugal four” of the Netherlands, Austria, Sweden and Denmark looking for there to be loans rather than grants. Their support for the fund will be necessary as it requires the unanimous approval of the member states.

The ECB a day earlier should be a non event (see DB’s preview here) with maybe some focus on any comments from President Lagarde on the German Constitutional Court, now that the German Bundestag has passed a motion on proportionality. The BoJ meeting on Wednesday should also be a relatively tame affair (see DB’s preview here ). Also in the world of central banks the Canadian, Korean and Indonesian policy makers meet and the Fed release their Beige Book on Wednesday.

Moving on to data releases, the main highlight is likely to be China’s Q2 GDP release on Thursday. Our economists are expecting a notable rebound in GDP growth to +3% year-on-year in Q2, following the -6.8% contraction in Q1. At the same time, there’ll also be the release of retail sales and industrial production for June, with our economists expecting an expansion in retail sales of +0.7% yoy in June (vs. -2.8% in May), and IP growth of +4.5% (vs. +4.4% in May).

Turning elsewhere, the US also has a number of data releases out next week, including an increasing amount of hard data for June. The highlights include the June CPI reading on Tuesday, before the industrial production number on Wednesday, retail sales on Thursday, and housing starts and building permits data on Friday, which should give us a clearer indication of how the economy has performed into the end of the quarter. Meanwhile the U.K. sees a number of data releases, including GDP for May, CPI for June, and unemployment in the three months to May. Another thing to look out for in the UK will be the release of the Office for Budget Responsibility’s Fiscal sustainability Report tomorrow, which will present alternative scenarios for the economy and public finances.

Earnings season kicks slowly into gear as 32 S&P 500 companies report along with a further 57 from the STOXX 600. The highlights include PepsiCo today, JPMorgan, Citigroup and Wells Fargo tomorrow, UnitedHealth Group, ASML, Goldman Sachs, US Bancorp, BNY Mellon on Wednesday, Johnson & Johnson, Netflix, Bank of America, Abbott Laboratories and Morgan Stanley on Thursday and on Friday, there’s Danaher, Honeywell International and BlackRock.

Back to last week, where markets were generally constructive even as the outlook for the virus has continued to worsen in recent weeks, especially in the US and Emerging Markets. The S&P 500 gained +1.76% (+1.05% Friday) on the week, and now sits just under 1.5% away from being flat on the year just as earning season is about to begin. The tech-focused Nasdaq greatly outperformed last week, rallying +4.01% (+0.66% Friday) led primarily by the index’s most heavily weighted stocks. European equities generally underperformed the S&P with the Stoxx 600 gaining a lesser +0.38% (+0.88% Friday) over the five days. Overall European bourses were mixed with the DAX (+0.84%), and FTSE MIB (+0.21%) up on the week, while indices such as the IBEX (-1.11%) and CAC (-0.73%) pulled back. Asian indices were even more disparate as Chinese stocks saw a large rise with the CSI 300 gaining +7.55% but with the Nikkei (-0.07%) and Kospi (-0.10%) largely unchanged over the week.

Core sovereign bonds rose as US 10yr Treasury yields fell -2.5bps (+3.1bps Friday) to finish at 0.645%, while 10yr Bund yields fell -3.3bps (-0.2bps Friday) to -0.47%. In other fixed income, HY cash spreads tightened on both sides of the Atlantic as US HY spreads tightened -4bps (-1bps Friday) and Europe HY tightened -1bps (+2bps Friday).

The dollar fell -0.54% on the week to its lowest weekly close since the first week of March. Against this backdrop and with global yields continuing to fall, gold gained +1.28% (-0.27% Friday). It was the 5th straight weekly gain for the yellow metal and took it to its highest weekly close since 2011. In other metals, copper rose +5.62% on the week to levels last seen in April of last year, while silver gained +3.88% to its highest value since September 2019.

Ahead of this Friday’s summit of EU leaders on the bloc’s long-term budget and the recovery fund, European Council President Michel issued new proposals on Friday that sought to achieve agreement between the member states. These maintained the existing plan to distribute €500bn in grants and €250bn in loans to member states. However, budget rebates would continue for fiscally conservative states such as the Netherlands, and repayments would be brought forward. He also proposed a Brexit reserve of €5bn that would support against “unforeseen consequences” in the member states and sectors most affected.

On the data front, we got French and Italian industrial production for May, both came ahead of forecasts. Italian industrial output rose +42.1% (vs. +24.0% expected) after falling by -20.5% in April. France saw a similar rebound, jumping up +19.6% (vs. +15.4% expected) after falling a nearly identical -20.6% the month prior. We also saw the June PPI reading from the US, where prices fell unexpectedly. PPI fell -0.2% (vs. +0.4% expected) after the month prior saw them rise +0.4%. It was the fourth monthly decline out of the last five.

via ZeroHedge News https://ift.tt/2ZpbT8Q Tyler Durden

Global Coronavirus Cases Top 13 Million As US 7-Day Average Hits Record Highs: Live Updates

Global Coronavirus Cases Top 13 Million As US 7-Day Average Hits Record Highs: Live Updates

Tyler Durden

Mon, 07/13/2020 – 07:29

It seems most of the popular tallies of coronavirus cases and deaths are in agreement that the US added only 59,017 (per JHU) or

58,147 (per Worldometer) cases on Sunday, the first day that the number of new cases fell short of 60k since early last week. Worldometer reported 3,414,042 cases at the end of day on Sunday, along with 137,784 deaths after 379 new deaths were confirmed.

While the number of new cases moved back below 60k, despite Florida’s record-smashing new-cases number from Sunday, the number of deaths recorded across the US dipped back below 500. So while the 7-day average for cases climbed to new all-time highs…

…the 7-day average for deaths ticked lower after hitting its highest level since mid-June.

The deceleration in the US helped ease yesterday’s global total, which was below the 200k for the first time in days.

Sunday’s numbers helped push the global case total to 13,049,461, moving above 13 million, the latest important psychological threshold.

Meanwhile, the number of new deaths was below 5k…

…bringing the global death toll to 571,812, as the global death toll draws inexorably nearer to 600k.

As the outbreak intensifies in Australia, China’s Ministry of Foreign Affairs and its embassy in Canberra on Monday have jointly advised Chinese citizens traveling to Australia to exercise caution. However, in addition to the resurgence in COVID-19, they also warned about “racism” and “anti-Chinese sentiment” as Beijing continues to punish Canberra for backing the US in its campaign against Huawei.

Australia, along with the US, is a part of the powerful “Five Eyes” intelligence partnership that China has been desperately seeking to compromise.

With its schools temporarily closed, Hong Kong reported another 52 new cases of coronavirus Monday, including 41 that were locally transmitted, health authorities confirmed. Tokyo just confirmed 119 new infections, sources tell Nikkei, with cases coming in below 120 for the first time in 5 days.

After crossing the 850k case threshold, cementing its status as the third-worst outbreak in the world behind the US and Brazil, India reported yet another record single-day jump in coronavirus cases, with 28,701 new infections reported in the last 24 hours. This brought India’s total to 878,254. The death toll, meanwhile, has climbed to 23,174, up 500 since Sunday morning. Meanwhile, South Korea confirmed 62 new cases, up from 44 a day ago, with total infections reaching 13,479, with 289 deaths.

via ZeroHedge News https://ift.tt/3gUk9Ua Tyler Durden

Chipmaker Analog Devices Agrees To Buy Rival Maxim Integrated In Biggest Deal Of The Year

Chipmaker Analog Devices Agrees To Buy Rival Maxim Integrated In Biggest Deal Of The Year

Tyler Durden

Mon, 07/13/2020 – 06:44

A deal that was teased last night by WSJ has just been officially confirmed: semiconductor maker Analog Devices has agreed to buy rival Maxim Integrated Products for roughly $20.91 billion all in stock, for what many M&A experts believe could be the largest deal of the year.

It comes as more semiconductor makers seek scale and more diverse offerings in an ultracompetitive market where Apple just dealt veteran player Intel a major blow by cutting out its chips. As computer chips are implanted in more items from cars to household products – continuing to build on the so-called “Internet of Things”.

According to the terms disclosed in a press release, Maxim stockholders will receive 0.630/share of Analog Devices stock for each share of Maxim common stock they hold when the deal closes.

While Analog’s chips focusing mor eon computing, Maxim’s semiconductors are used in settings from automobiles to health-care, sectors where Analog doesn’t have a large presence. According to WSJ, the deal talks have been ongoing for years. But the time wasn’t right until the present market chaos. Analog has a market value of roughly $46 billion and is based in Norwood, Mass.

Read the press release here:

Analog Devices, Inc. (Nasdaq: ADI) and Maxim Integrated Products, Inc. (Nasdaq: MXIM) today announced that they have entered into a definitive agreement under which ADI will acquire Maxim in an all stock transaction that values the combined enterprise at over $68 billion2. The transaction, which was unanimously approved by the Boards of Directors of both companies, will strengthen ADI as an analog semiconductor leader with increased breadth and scale across multiple attractive end markets.

Under the terms of the agreement, Maxim stockholders will receive 0.630 of a share of ADI common stock for each share of Maxim common stock they hold at the closing of the transaction. Upon closing, current ADI stockholders will own approximately 69 percent of the combined company, while Maxim stockholders will own approximately 31 percent. The transaction is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes.

“Today’s exciting announcement with Maxim is the next step in ADI’s vision to bridge the physical and digital worlds. ADI and Maxim share a passion for solving our customers’ most complex problems, and with the increased breadth and depth of our combined technology and talent, we will be able to develop more complete, cutting-edge solutions,” said Vincent Roche, President and CEO of ADI.

“Maxim is a respected signal processing and power management franchise with a proven technology portfolio and impressive history of empowering design innovation. Together, we are well-positioned to deliver the next wave of semiconductor growth, while engineering a healthier, safer and more sustainable future for all.”

“For over three decades, we have based Maxim on one simple premise – to continually innovate and develop high-performance semiconductor products that empower our customers to invent. I am excited for this next chapter as we continue to push the boundaries of what’s possible, together with ADI. Both companies have strong engineering and technology know-how and innovative cultures.

Working together, we will create a stronger leader, delivering outstanding benefits to our customers, employees and shareholders,” said Tunç Doluca, President and CEO of Maxim Integrated.

Upon closing, two Maxim directors will join ADI’s Board of Directors, including Maxim President and CEO, Tunç Doluca.

Compelling Strategic and Financial Rationale

Industry Leader with Increased Global Scale: The combination strengthens ADI’s analog semiconductor leadership position with expected revenue of $8.2 billion1 and free cash flow of $2.7 billion1 on a pro forma basis. Maxim’s strength in the automotive and data center markets, combined with ADI’s strength across the broad industrial, communications and digital healthcare markets are highly complementary and aligned with key secular growth trends. With respect to power management, Maxim’s applications-focused product offerings complement ADI’s catalog of broad market products.

Enhanced Domain Expertise & Capabilities: Combining best-in-class technologies will enhance ADI’s depth of domain expertise and engineering capabilities from DC to 100 gigahertz, nanowatts to kilowatts and sensor to cloud, with more than 50,000 products. This will enable the combined company to offer more complete solutions, serve more than 125,000 customers and capture a larger share of a $60 billion total addressable market3.

Shared Passion for Innovation-led Growth: The combination brings together similar cultures focused on talent, innovation and engineering excellence with more than 10,000 engineers and approximately $1.5 billion1 in annual research and development investment. The combined company will continue to be a destination for the most talented engineers in multiple domains.

Earnings Accretion & Cost Savings: This transaction is expected to be accretive to adjusted EPS in 18 months subsequent to closing with $275 million of cost synergies by the end of year two, driven primarily by lower operating expenses and cost of goods sold. Additional cost synergies from manufacturing optimization are expected to be realized by the end of year three subsequent to closing.

Strong Financial Position & Cash Flow Generation: ADI expects the combined company to yield a stronger balance sheet, with a pro forma net leverage ratio of approximately 1.2×4. This transaction is also expected to be accretive to free cash flow at close, enabling additional returns to shareholders.

Timing and Approvals

The transaction is expected to close in the summer of 2021, subject to the satisfaction of customary closing conditions, including receipt of U.S. and certain non-U.S. regulatory approvals, and approval by stockholders of both companies.

Advisors

Morgan Stanley served as lead financial advisor to ADI. BofA Securities also served as a financial advisor. Wachtell, Lipton, Rosen & Katz served as legal counsel.

J.P. Morgan served as exclusive financial advisor to Maxim, and Weil, Gotshal & Manges LLP served as legal counsel.

via ZeroHedge News https://ift.tt/2C8Kz5N Tyler Durden

Let People Volunteer as Coronavirus Vaccine Testers

topicsscience

Accelerating the development of an effective vaccine against COVID-19 is an urgent global priority. The Trump administration has launched an “Operation Warp Speed” initiative that ambitiously aims to have 300 million doses of a coronavirus vaccine by January 2021. While pharmaceutical companies around the world are developing 120 different vaccine candidates, only a few thus far have begun testing their vaccines in people. Among those conducting phase one and phase two clinical trials are Moderna Therapeutics, Pfizer, and Inovio Pharmaceuticals in the United States. Phase one and two trials seek to establish the safety of the vaccine and the immune system’s reaction to it.

The conventional next step would be phase three trials, in which thousands of participants at risk of the targeted infection are randomized to receive either the vaccine or a control placebo. The trial participants are then monitored by researchers as they go about their usual lives to see how many of the vaccinated people (vs. those in the placebo group) actually come down with the disease. This stately process of evaluation takes a considerable amount of time to unfold.

Human challenge trials, also known as controlled human infection studies, would greatly speed up the process of identifying effective vaccines and treatments for the virus responsible for the COVID-19 pandemic. Consequently, some prominent bioethicists are arguing that it’s time to recruit some healthy and willing young people, inject them with various experimental coronavirus vaccines, and then expose them to the virus to see if any of the vaccines work. Instead of waiting around for the virus to find (vaccinated and unvaccinated) folks in the wild—as researchers do in regular phase three trials—human challenge trials speed things up by purposely bringing the virus to the study participants. sci

Setting aside the misery of illness, the risk of death from the coronavirus for folks under age 50 is about 1 in 200. Bioethicists in favor of human challenge trials argue that they are ethical on the grounds that we’re constantly allowing people to engage in risky activities, such as volunteer firefighting, working in infectious disease wards, or serving as living organ donors. In addition, volunteers in such trials would be carefully monitored for the disease and therefore would likely be safer than folks relying on the general health care system to treat them. The bioethicists also properly insist on obtaining robust and ongoing informed consent from the volunteers.

In May, a group of bioethicists led by Northwestern’s Seema Shah argued in Science that human challenge trials for coronavirus vaccines would have “high social value” by providing “substantial benefits for much of the world’s population.”

Besides the satisfaction of perhaps playing a role in saving hundreds of thousands of lives and hastening the end of the lockdowns, the volunteers would earn some cash for their troubles. Shah and her colleagues noted that “fairness seems to demand offering participants compensation for their time.” It certainly does. They proposed giving several thousand dollars to each American volunteer.

As of early June, more than 28,000 people had volunteered to participate in coronavirus vaccine human challenge trials on 1DaySooner, a website organized by a group of young researchers.

In April, Reps. Bill Foster (D–Ill.) and Donna Shalala (D–Fla.), along with nearly 40 other members of Congress, sent a letter to the Food and Drug Administration (FDA) urging the agency to consider expediting “challenge trials that involve deliberately infecting volunteers who have received candidate vaccines or placebos to confirm the efficacy of those vaccines and are at very low risk of serious disease from the infection.”

In a statement to NBC in May, the FDA tepidly observed that “because these studies involve exposing volunteers to the virus, the studies raise a variety of potential scientific, feasibility, and ethical issues.” But the agency added that it would “work with those who are interested in conducting human challenge trials to help them evaluate these issues.”

As of press time, pharmaceutical companies such as Moderna and Pfizer seemed content to dawdle along with conventional phase three trials, but we can hope that that will change. Human challenge trials could really crank up the warp factor in the search for an effective COVID-19 vaccine.

from Latest – Reason.com https://ift.tt/38RS2lN
via IFTTT

Let People Volunteer as Coronavirus Vaccine Testers

topicsscience

Accelerating the development of an effective vaccine against COVID-19 is an urgent global priority. The Trump administration has launched an “Operation Warp Speed” initiative that ambitiously aims to have 300 million doses of a coronavirus vaccine by January 2021. While pharmaceutical companies around the world are developing 120 different vaccine candidates, only a few thus far have begun testing their vaccines in people. Among those conducting phase one and phase two clinical trials are Moderna Therapeutics, Pfizer, and Inovio Pharmaceuticals in the United States. Phase one and two trials seek to establish the safety of the vaccine and the immune system’s reaction to it.

The conventional next step would be phase three trials, in which thousands of participants at risk of the targeted infection are randomized to receive either the vaccine or a control placebo. The trial participants are then monitored by researchers as they go about their usual lives to see how many of the vaccinated people (vs. those in the placebo group) actually come down with the disease. This stately process of evaluation takes a considerable amount of time to unfold.

Human challenge trials, also known as controlled human infection studies, would greatly speed up the process of identifying effective vaccines and treatments for the virus responsible for the COVID-19 pandemic. Consequently, some prominent bioethicists are arguing that it’s time to recruit some healthy and willing young people, inject them with various experimental coronavirus vaccines, and then expose them to the virus to see if any of the vaccines work. Instead of waiting around for the virus to find (vaccinated and unvaccinated) folks in the wild—as researchers do in regular phase three trials—human challenge trials speed things up by purposely bringing the virus to the study participants. sci

Setting aside the misery of illness, the risk of death from the coronavirus for folks under age 50 is about 1 in 200. Bioethicists in favor of human challenge trials argue that they are ethical on the grounds that we’re constantly allowing people to engage in risky activities, such as volunteer firefighting, working in infectious disease wards, or serving as living organ donors. In addition, volunteers in such trials would be carefully monitored for the disease and therefore would likely be safer than folks relying on the general health care system to treat them. The bioethicists also properly insist on obtaining robust and ongoing informed consent from the volunteers.

In May, a group of bioethicists led by Northwestern’s Seema Shah argued in Science that human challenge trials for coronavirus vaccines would have “high social value” by providing “substantial benefits for much of the world’s population.”

Besides the satisfaction of perhaps playing a role in saving hundreds of thousands of lives and hastening the end of the lockdowns, the volunteers would earn some cash for their troubles. Shah and her colleagues noted that “fairness seems to demand offering participants compensation for their time.” It certainly does. They proposed giving several thousand dollars to each American volunteer.

As of early June, more than 28,000 people had volunteered to participate in coronavirus vaccine human challenge trials on 1DaySooner, a website organized by a group of young researchers.

In April, Reps. Bill Foster (D–Ill.) and Donna Shalala (D–Fla.), along with nearly 40 other members of Congress, sent a letter to the Food and Drug Administration (FDA) urging the agency to consider expediting “challenge trials that involve deliberately infecting volunteers who have received candidate vaccines or placebos to confirm the efficacy of those vaccines and are at very low risk of serious disease from the infection.”

In a statement to NBC in May, the FDA tepidly observed that “because these studies involve exposing volunteers to the virus, the studies raise a variety of potential scientific, feasibility, and ethical issues.” But the agency added that it would “work with those who are interested in conducting human challenge trials to help them evaluate these issues.”

As of press time, pharmaceutical companies such as Moderna and Pfizer seemed content to dawdle along with conventional phase three trials, but we can hope that that will change. Human challenge trials could really crank up the warp factor in the search for an effective COVID-19 vaccine.

from Latest – Reason.com https://ift.tt/38RS2lN
via IFTTT

How High Can Gold Go In 2020?

How High Can Gold Go In 2020?

Tyler Durden

Mon, 07/13/2020 – 06:00

Written by Sam Laakso from Voima Insight.

Gold has had a great run over the past year. Gold prices have risen in every single currency on earth and in many currencies gold prices are up well over 30 percent from last summer.

In early January, I published an article (in Finnish) in a local financial newspaper where I articulated why gold would rise to $1800 per ounce during the first half of the year – a rise of 20 percent in just six months. As it turns out, gold did just that on the last day of June meaning that in the end my estimation was correct.

Although more volatile than expected, gold price in New York reached my target of $1800 per ounce during the first half of 2020 on the very last day. It has hit records against all other currencies.

So, what is my forecast for gold for the rest of 2020? How high can gold go this year?

My estimation

I see that there is an extremely optimistic atmosphere around gold at the moment. Investment banks are upping their target prices for gold left and right and my favorite sentiment metric, Twitter, has exploded after gold breached $1800.

I am known as a cycles analyst. In the past I have written rather extensively about how cycles work in the financial markets. You can read more about this topic at SKAL Capital and in my Thesis.

The cycles theory revolves around the thought that, as nature in itself, human nature cyclical cycling between optimism and pessimism. This transmits to the way people buy and sell financial assets and thus the prices of stocks, bonds, commodities, and gold also rise and fall in identifiable cycles.

Right now, the markets are telling me that the gold market is excessively optimistic due to the rise in gold prices over the past three months and that the cycle in gold is mature and thus ready to start the declining phase of the cycle. Once optimism reaches an extreme, prices tend to start the declining phase of the cycle.

Gold has risen strongly over the first half of the year. As you can see, strong uptrends are often followed by falling prices highlighted in yellow and I think we are close to one of those declines.

 

So how exactly I think that the second half of the year is going to play out for gold?

I think that we are close to a short-term top in the price of gold. We have not seen a long and exhausting multi-week decline in the price of gold, which would wash out the highest optimism in gold, for six months.

We did see a short lived and sizable correction in March during the global coronavirus selloff, but since the sharp decline (buying opportunity) was erased just as quickly as it came, I argue that the mental damage to gold market sentiment was not big enough.

As I am writing this article the price of gold is at an eight-year high, or $1816 per ounce to be exact, when measured in US dollars. However, optimism in the gold market is just as high. Calls for $1900 and $2000 gold are everywhere I look at.

The big picture fundamentals for gold are crystal clear and in favor for higher gold prices in the years to come. Central banks around the world are printing money faster than governments are able to spend it at zero percent interest rates = insanity. This type of reckless spending is definitely good for gold prices in the long run.

However, over the next two to three months I would not be surprised to see a multi week decline which would serve as a great buying opportunity in the big picture.

Gold is at a level of extreme resistance – breaking to new all-time highs not seen since 2011 – I think that it is likely that gold will start a corrective move before breaking to new all-time highs.

I think that once we get a short-term top on gold, over the next few weeks, we will see a move down to $1670 and possibly all the way down to $1600 in a painstakingly long but necessary correction. A multi week correction will wash out the excessive optimism surrounding gold. At the bottom of the correction, you will not be hearing calls for $2000 gold like you see now.

After we are done with the correction, I think that gold has a fair shot of reaching $1900 during the second half of this year. This would be the third consecutive year when gold has risen nearly 20% relative to the US dollar.

Another way of looking at it is that the US dollar has lost almost half of its purchasing power relative to gold in just three years.

How to act?

If you do not own any gold – buy it now with the big picture in mind. Even though I have been accurate with my latest predictions for gold in 2019 and 2020 my predictions are merely estimates and so I do not advise waiting for my prediction of a better buying opportunity to fulfill especially if you do not own any gold already.

I think that the pullback will act as a great buying opportunity for those who already have gold but are looking to add to their holdings – I certainly am.

My advice for everyone thinking about buying gold has been simple for many years:

1) Decide how much of your money you are willing convert into gold

2) Buy gold with 50% of the amount immediately

3) Wait for a few months

a. If gold prices decline – Great! You have chance to buy lower

b. If gold prices rise – you have already bought the first half at lower prices and so you can buy more with peace in mind

Either way you are well off once you own at least some physical gold.

In early 2019, I published my thesis titled “The Future of Gold from 2019 to 2039” in which I explained in detail why I think that gold prices will reach at least $5000 over the next five to ten years. If you are interested in my view of the big picture for gold you can find my Thesis  here.

My long-term view still holds today – I think that gold prices are likely to rise every year for the next five to ten years.

The views expressed on Voima Insight are those of the author(s) and do not necessarily reflect the official views or position of Voima Gold.

via ZeroHedge News https://ift.tt/2ASgxCA Tyler Durden

GM Cutting Third Shift At Missouri Plant After Workers Fail To Show Up Due To COVID Fears

GM Cutting Third Shift At Missouri Plant After Workers Fail To Show Up Due To COVID Fears

Tyler Durden

Mon, 07/13/2020 – 05:30

GM is on the verge of cutting its third shift at its mid-size truck assembly plant in Wentzville, Missouri after coronavirus fears have caused employees to stay home. 

Missouri reported its third largest daily increase in new cases of the virus and on Saturday, GM sent its plant workers an “urgent” notification informing them of the change to a two-shift operation, according to the Detroit News.

GM spokesman David Barnas said: “We believe in the short term a two-shift operating plan will allow us to operate as efficiently as possible and accommodate team members who are not reporting to work due to concerns about COVID-19 in the local community.”

The area’s local Pandemic Task Force reported a rolling seven-day average of hospital admissions in the area for both suspected and confirmed COVID-19 cases increased to 24 on Friday, up from 23 on Thursday. It is the highest this number has been since back in May. 

As a result, GM issued an alert saying: “We will begin canvassing 3rd shift employees to identify their desire to either participate in a temporary layoff or express their interest to be considered for available work opportunities.” 

Each shift has about 1,250 employees and GM says it doesn’t know how many people will be affected by the cuts. The company says it’ll work to get back to 3 shifts as soon as possible. 

Barnas continued: “People on our team should not be concerned about coming to work. GM Wentzville is following multi-layered safety protocols that are working very well to keep people safe by reducing the possibility that COVID-19 can enter the plant and preventing any spread within the plant.”

The Wentzville plant is responsible for the Chevrolet Colorado and GMC Canyon mid-size trucks and Chevy Express and GMC Savana full-size vans. GM had just re-opened its plants during the week of May 18. The company is in the midst of dealing with low inventory levels as a result of the pandemic. 

“We’ve got jobs for three shifts at Wentzville because of strong dealer and customer demand for mid-size trucks and vans. It will take us longer to rebuild inventory than it would if we were operating at a stable three full shifts of production,” Barnas concluded.

A UAW international spokesman said: “While we can’t comment right now we can say we are monitoring the situation.” 

via ZeroHedge News https://ift.tt/2Wf53k7 Tyler Durden